Tempus AI

Tempus AI is an artificial intelligence platform built for precision medicine, with a specific focus on oncology. Developed by Tempus, the platform applies genomic analysis and machine learning to help clinicians select cancer treatments that are matched to a patient’s molecular profile. It is designed for use by oncologists, cancer care teams, and healthcare institutions rather than individual consumers.

How Tempus AI works

Tempus AI ingests molecular and genomic data from patient samples and runs it against a library of clinical and molecular information. The platform identifies patterns in that data to predict how a patient may respond to specific treatments. It also cross-references current clinical trials to surface enrollment opportunities that match a patient’s profile. The core workflow moves from genomic sequencing through data analysis to a ranked set of treatment and trial options that a physician can evaluate alongside standard clinical judgment.

• AI Genomic Analysis: Processes sequencing data to identify clinically relevant mutations and biomarkers.
• Cancer Treatment Optimization: Uses molecular findings to rank treatment options by predicted relevance to the patient’s cancer type and profile.
• Clinical Trial Matching: Automatically matches patient molecular data against active trials to flag eligibility.
• Molecular Data Library: Draws on a repository of de-identified clinical and genomic records to contextualize findings.
• Treatment Response Prediction: Generates predictions on how likely a given treatment is to produce a response based on similar molecular profiles.

Strengths

• Deep oncology focus means the platform is purpose-built for one of the most complex clinical use cases in medicine, rather than a general-purpose health tool stretched to cover cancer.
• Clinical trial matching is integrated directly into the genomic workflow, which reduces the manual search burden on care teams looking for trial options.
• The molecular data library provides context that a single institution’s own patient records typically cannot match in volume or diversity.
• Treatment response prediction gives oncologists a structured data point to weigh alongside their own clinical experience, without replacing that judgment.

Limitations

• Access is restricted to healthcare institutions. Individual patients cannot use the platform directly, and its value depends entirely on whether a patient’s care team or cancer center has a relationship with Tempus.
• Pricing is institutional and not publicly listed, which makes it difficult for smaller oncology practices or community hospitals to evaluate cost before engaging with the company.
• The platform is narrowly scoped to oncology. Clinicians dealing with non-cancer conditions will find no utility here.
• Like all genomic AI tools, outputs are probabilistic, not deterministic. A treatment response prediction is a signal, not a guarantee, and results depend heavily on the quality and completeness of the input sequencing data.
• Integration with existing electronic health record systems and lab workflows varies by institution and may require significant technical coordination to implement.

Who it is for

Tempus AI is built for oncologists, molecular tumor boards, and cancer center administrators who want to incorporate genomic data more systematically into treatment decisions. It is most useful at institutions that already perform next-generation sequencing and want a structured layer of AI analysis on top of that data. Patients who want to understand whether their care team has access to precision medicine tools like this should ask their oncologist or cancer center directly. It is not a consumer application and does not have a patient-facing interface.

How it compares

Tempus AI operates in a completely different segment of health AI than most tools in this directory. Consumer health platforms like Headspace, which uses AI to support mental wellness and guided meditation, or Flo Health, which applies AI to menstrual and reproductive health tracking, serve individuals managing everyday health goals. Tempus AI targets clinical decision-making in life-threatening disease contexts, with genomic data as the foundation rather than user-reported symptoms or lifestyle inputs. The comparison is not one of better or worse; these tools solve fundamentally different problems for fundamentally different users. Someone evaluating Tempus AI is typically a hospital administrator or oncologist assessing institutional software, not a consumer browsing health apps.